JÃ¼rgen Burhenne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3444080/publications.pdf

Version: 2024-02-01

201	7,172	44069	76900
papers	citations	48 h-index	74 g-index

201	201	201	7338
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease. Gut, 2022, 71, 842-844.	12.1	7
2	Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drugâ€Drug Interaction Trial in Healthy Adults. Clinical Pharmacology in Drug Development, 2022, 11, 285-290.	1.6	3
3	Perpetrator Characteristics of Azole Antifungal Drugs on Three Oral Factor Xa Inhibitors Administered as a Microdosed Cocktail. Clinical Pharmacokinetics, 2022, 61, 97-109.	3.5	8
4	Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?. European Journal of Pharmaceutical Sciences, 2022, 169, 106076.	4.0	5
5	Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matricesâ€"A Practical Example. Molecules, 2022, 27, 690.	3.8	2
6	Low Exposure to Direct Oral Anticoagulants Is Associated with Ischemic Stroke and Its Severity. Journal of Stroke, 2022, 24, 88-97.	3.2	8
7	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. Biomedicines, 2022, 10, 1.	3.2	17
8	Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue. Pharmaceutics, 2022, 14, 762.	4.5	0
9	Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. European Journal of Clinical Pharmacology, 2022, 78, 975-987.	1.9	3
10	Functional Characterization of the Solute Carrier LAT-1 (SLC7A5/SLC2A3) in Human Brain Capillary Endothelial Cells with Rapid UPLC-MS/MS Quantification of Intracellular Isotopically Labelled L-Leucine. International Journal of Molecular Sciences, 2022, 23, 3637.	4.1	4
11	MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nature Cancer, 2022, 3, 471-485.	13.2	73
12	Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. Pharmaceuticals, 2022, 15, 694.	3.8	6
13	LGG-25. The first-in-class ERK inhibitor ulixertinib (BVD-523) shows activity in MAPK-driven pediatric low-grade glioma models as single agent and in combination with MEK inhibitors or senolytics. Neuro-Oncology, 2022, 24, i93-i93.	1.2	0
14	Early or deferred initiation of efavirenz during rifampicinâ€based TB therapy has no significant effect on CYP3A induction in TBâ€HIV infected patients. British Journal of Pharmacology, 2021, 178, 3294-3308.	5.4	9
15	A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy. Leukemia, 2021, 35, 701-711.	7.2	56
16	Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. Journal of Clinical Pharmacology, 2021, 61, 472-479.	2.0	6
17	Application of triple quadrupole tandem mass spectrometry to the bioanalysis of collision-induced dissociation-resistant cyclic peptides â€“ Ultra-sensitive quantification of the somatostatin-analog pasireotide utilizing UHPLC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 194, 113728.	2.8	3
18	Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity. Journal of Clinical Pharmacology, 2021, 61, 789-798.	2.0	5

#	Article	IF	Citations
19	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinaseâ€Positive Nonâ€Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat. Clinical and Translational Science, 2021, 14, 487-491.	3.1	9
20	Approaching sites of action of drugs in clinical pharmacology: New analytical options and their challenges. British Journal of Clinical Pharmacology, 2021, 87, 858-874.	2.4	9
21	Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. Molecules, 2021, 26, 1281.	3.8	11
22	Differential Effect of a Continental Breakfast on Tacrolimus Formulations With Different Release Characteristics. Clinical Pharmacology in Drug Development, 2021, 10, 899-907.	1.6	3
23	Desorption/Ionization-MS Methods for Drug Quantification in Biological Matrices and Their Validation Following Regulatory Guidance. Analytical Chemistry, 2021, 93, 7152-7163.	6.5	8
24	Intact plasma quantification of the large therapeutic lipopeptide bulevirtide. Analytical and Bioanalytical Chemistry, 2021, 413, 5645-5654.	3.7	4
25	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1176, 122781.	2.3	2
26	Rapid and Sensitive Quantification of Intracellular Glycyl-Sarcosine for Semi-High-Throughput Screening for Inhibitors of PEPT-1. Pharmaceutics, 2021, 13, 1019.	4.5	3
27	Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. Pharmaceutics, 2021, 13, 1498.	4.5	3
28	Rapid drug detection in whole blood droplets using a desorption electrospray ionization static profiling approach â€“ a proofâ€ofâ€concept. Rapid Communications in Mass Spectrometry, 2020, 34, e8614.	1.5	11
29	Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents. Clinical Pharmacokinetics, 2020, 59, 643-654.	3.5	5
30	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell, 2020, 182, 1252-1270.e34.	28.9	259
31	Development and Validation of an LCâ€“MS-Based Quantification Assay for New Therapeutic Antibodies: Application to a Novel Therapy against Herpes Simplex Virus. ACS Omega, 2020, 5, 24329-24339.	3.5	10
32	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDIâ€“IMâ€“MS/MS Assay. Cancers, 2020, 12, 1897.	3.7	14
33	New Insights Into the Pharmacokinetics of Vancomycin After Oral and Intravenous Administration: An Investigation in Beagle Dogs. Journal of Pharmaceutical Sciences, 2020, 109, 2090-2094.	3.3	6
34	An Underestimated Factor: The Extent of Cross-Reactions Modifying APIs in Surface-Modified Liposomal Preparations Caused by Comprised Activated Lipids. Molecules, 2020, 25, 4436.	3.8	2
35	Microdosing drugs: a versatile technique to detect and assess drugâ€“drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 447-448.	3.3	0
36	Ultra-sensitive bioanalysis of the therapeutic peptide exenatide for accurate pharmacokinetic analyses at effective plasma concentrations utilizing UPLC-MS/MS. Journal of Pharmaceutical Analysis, 2020, 10, 233-239.	5.3	5

#	Article	IF	Citations
37	Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drugâ€“drug interactions with different perpetrator drugs. British Journal of Clinical Pharmacology, 2020, 86, 1632-1641.	2.4	14
38	Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations. Frontiers in Pharmacology, 2020, 11, 26.	3.5	12
39	Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial. Trials, 2020, 21, 584.	1.6	3
40	Advances in Clinical Pharmacology: Rapid Detection of Small Molecules in Solid Samples at Atmospheric Pressure Using Desorption Electrospray Ionization. OMICS A Journal of Integrative Biology, 2020, 24, 53-54.	2.0	4
41	Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling. Journal of the American Society for Mass Spectrometry, 2020, 31, 742-751.	2.8	13
42	Post-extraction disulfide bond cleavage for MS/MS quantification of collision-induced dissociation-resistant cystine-cyclized peptides and its application to the ultra-sensitive UPLC-MS/MS bioanalysis of octreotide in plasma. Analytica Chimica Acta, 2020, 1114, 42-49.	5.4	5
43	Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics. Journal of Pharmaceutical and Biomedical Analysis, 2020, 186, 113276.	2.8	2
44	Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers, 2020, 12, 793.	3.7	14
45	An ultra-sensitive UHPLC-MS/MS assay for the quantification of orally administered vancomycin in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2019, 174, 633-638.	2.8	8
46	An ultrasensitive UPLCâ€“MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs. Bioanalysis, 2019, 11, 887-898.	1.5	9
47	Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis, 2019, 11, 1459-1467.	1.5	12
48	Unexpected excessive apixaban exposure: case report of a patient with polymorphisms of multiple apixaban elimination pathways. BMC Pharmacology & Toxicology, 2019, 20, 53.	2.4	15
49	Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International Journal of Molecular Sciences, 2019, 20, 4267.	4.1	10
50	Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. British Journal of Clinical Pharmacology, 2019, 85, 2310-2320.	2.4	17
51	Prolongedâ€Release Tacrolimus Is Less Susceptible to Interaction With the Strong <scp>CYP</scp>3A Inhibitor Voriconazole in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2019, 106, 1290-1298.	4.7	19
52	Microdosed midazolam for the determination of cytochrome P450 3A activity: Development and clinical evaluation of a buccal film. European Journal of Pharmaceutical Sciences, 2019, 135, 77-82.	4.0	3
53	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. Journal of Hepatology, 2019, 70, e81.	3.7	93
54	Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drugâ€“Drug Interactions with Potential Perpetrator Drugs. Clinical Pharmacokinetics, 2019, 58, 1155-1163.	3.5	12

#	Article	IF	Citations
55	Perpetrator effects of ciclosporin (Pâ€glycoprotein inhibitor) and its combination with fluconazole (CYP3A inhibitor) on the pharmacokinetics of rivaroxaban in healthy volunteers. British Journal of Clinical Pharmacology, 2019, 85, 1528-1537.	2.4	21
56	Simultaneous quantification of the CYP2D6 substrate yohimbine, its metabolite 11-OH-yohimbine, and the CYP2D6 inhibitor paroxetine in human plasma. Analytical Methods, 2019, 11, 5976-5983.	2.7	1
57	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. Clinical Epigenetics, 2019, 11, 188.	4.1	27
58	Elucidating the beneficial effects of melphalan, adriamycin, and corticoids in combination with bortezomib against multiple myeloma in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 461-466.	3.0	0
59	In Vivo CYP3A Activity in Palliative Care Patients: Study Protocol for a Single Arm Prospective Trial. Journal of Palliative Medicine, 2018, 21, 686-688.	1.1	3
60	Systematic identification of suspected anthelmintic benzimidazole metabolites using LCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2018, 151, 151-158.	2.8	9
61	Reply to Truffot et al. Clinical Infectious Diseases, 2018, 66, 1644-1646.	5.8	0
62	High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. Gastroenterology, 2018, 154, 1543-1545.	1.3	27
63	Simultaneous quantification of direct oral anticoagulants currently used in anticoagulation therapy. Journal of Pharmaceutical and Biomedical Analysis, 2018, 148, 238-244.	2.8	37
64	Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype. Scientific Reports, 2018, 8, 16316.	3.3	8
65	Rivaroxaban and macitentan can be coadministered without dose adjustment but the combination of rivaroxaban and St John's wort should be avoided. British Journal of Clinical Pharmacology, 2018, 84, 2903-2913.	2.4	17
66	Dried-Blood-Spot Technique to Monitor Direct Oral Anticoagulants: Clinical Validation of a UPLCâ€“MS/MS-Based Assay. Analytical Chemistry, 2018, 90, 9395-9402.	6.5	33
67	Identification, Biosynthesis, and Decapping of NAD-Capped RNAs in B.Âsubtilis. Cell Reports, 2018, 24, 1890-1901.e8.	6.4	61
68	Higher chlorzoxazone clearance in obese children compared with none-obese peers, an open-label explorative pharmacokinetic study of CYP2E1 activity. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO2-15-20.	0.0	0
69	Semisimultaneous Midazolam Administration to Evaluate the Time Course of CYP3A Activation by a Single Oral Dose of Efavirenz. Journal of Clinical Pharmacology, 2017, 57, 899-905.	2.0	11
70	Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment. Respiration, 2017, 94, 26-37.	2.6	19
71	Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure. Clinical Infectious Diseases, 2017, 65, 1033-1036.	5.8	11
72	Ultra-sensitive and selective quantification of endothelin-1 in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 84-90.	2.8	6

#	Article	IF	Citations
73	Autoinhibitory properties of the parent but not of the Nâ€oxide metabolite contribute to infusion rateâ€dependent voriconazole pharmacokinetics. British Journal of Clinical Pharmacology, 2017, 83, 1954-1965.	2.4	19
74	Intracellular vorinostat accumulation and its relationship to histone deacetylase activity in soft tissue sarcoma patients. Cancer Chemotherapy and Pharmacology, 2017, 80, 433-439.	2.3	7
75	Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient. Cancer Chemotherapy and Pharmacology, 2017, 80, 71-79.	2.3	5
76	Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
77	Simultaneous quantification of endothelin receptor antagonists and phosphodiesterase 5 inhibitors currently used in pulmonary arterial hypertension. Journal of Pharmaceutical and Biomedical Analysis, 2017, 143, 291-298.	2.8	14
78	Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. Biochemical Pharmacology, 2017, 145, 54-63.	4.4	10
79	A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model of the histone deacetylase (HDAC) inhibitor vorinostat for pediatric and adult patients and its application for dose specification. Cancer Chemotherapy and Pharmacology, 2017, 80, 1013-1026.	2.3	20
80	The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers â€" An in vitro and in vivo comparison. European Journal of Pharmaceutical Sciences, 2017, 108, 13-22.	4.0	18
81	Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactions. Oncology Letters, 2017, 14, 3185-3192.	1.8	6
82	Clinical feasibility of dried blood spots: Analytics, validation, and applications. Journal of Pharmaceutical and Biomedical Analysis, 2016, 130, 231-243.	2.8	109
83	Longâ€Term Effect of Rifampicinâ€Based Antiâ€TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8â€Hydroxyâ€Efavirenz in Ethiopian Patients. Journal of Clinical Pharmacology, 2016, 56, 1538-1549.	2.0	11
84	Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. Clinical Pharmacokinetics, 2016, 55, 1535-1545.	3.5	51
85	Treatment with rilpivirine does not alter plasma concentrations of the CYP3A substrates tadalafil and midazolam in humans. Journal of Antimicrobial Chemotherapy, 2016, 71, 2241-2247.	3.0	5
86	Vorinostat in refractory soft tissue sarcomas â€" Results of a multi-centre phase II trial of the German Soft Tissue Sarcoma and Bone Tumour Working Group (AIO). European Journal of Cancer, 2016, 64, 74-82.	2.8	28
87	Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 1091-1101.	3.0	5
88	Prevalence and risk factors for efavirenz-based antiretroviral treatmentâ€"associated severe vitamin D deficiency. Medicine (United States), 2016, 95, e4631.	1.0	18
89	Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its main metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1027, 207-213.	2.3	15
90	The Effect of Induction of <scp>CYP</scp>3A4 by St John's Wort on Ambrisentan Plasma Pharmacokinetics in Volunteers of known <scp>CYP</scp>2C19 Genotype. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 423-428.	2.5	19

#	Article	IF	Citations
91	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia, 2015, 63, 1850-1859.	4.9	13
92	Midazolam microdose to determine systemic and preâ€systemic metabolic <scp>CYP3A</scp> activity in humans. British Journal of Clinical Pharmacology, 2015, 79, 278-285.	2.4	59
93	Cellular uptake kinetics of bortezomib in relation to efficacy in myeloma cells and the influence of drug transporters. Cancer Chemotherapy and Pharmacology, 2015, 75, 281-291.	2.3	22
94	Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study. Pharmacogenomics, 2015, 16, 1047-1064.	1.3	19
95	Preâ€systemic Elimination of Tilidine: Localization and Consequences for the Formation of the Active Metabolite Nortilidine. Basic and Clinical Pharmacology and Toxicology, 2015, 116, 129-133.	2.5	4
96	Dried Blood Spot Technique for the Monitoring of Ambrisentan, Bosentan, Sildenafil, and Tadalafil in Patients with Pulmonary Arterial Hypertension. Analytical Chemistry, 2015, 87, 12112-12120.	6.5	20
97	Fetal calf sera can distort cell-based luminescent proteasome assays through heat-resistant chymotrypsin-like activity. Analytical Biochemistry, 2015, 471, 23-25.	2.4	2
98	Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome <scp>P450 3A4</scp> activity. British Journal of Clinical Pharmacology, 2014, 78, 1433-1440.	2.4	6
99	<scp>CYP3A</scp> activity in severe liver cirrhosis correlates with <scp>C</scp>hildâ€“<scp>P</scp>ugh and model for endâ€stage liver disease (<scp>MELD</scp>) scores. British Journal of Clinical Pharmacology, 2014, 77, 160-169.	2.4	53
100	Clarithromycin substantially increases steadyâ€state bosentan exposure in healthy volunteers. British Journal of Clinical Pharmacology, 2014, 77, 141-148.	2.4	17
101	Aprepitant, Granisetron, and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting After High-Dose Melphalan in Autologous Transplantation for Multiple Myeloma: Results of a Randomized, Placebo-Controlled Phase III Trial. Journal of Clinical Oncology, 2014, 32, 3413-3420.	1.6	73
102	Quantification of vorinostat and its main metabolites in plasma and intracellular vorinostat in PBMCs by liquid chromatography coupled to tandem mass spectrometry and its relation to histone deacetylase activity in human blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 964, 212-221.	2.3	14
103	Stability of the proteasome inhibitor bortezomib in cell based assays determined by ultra-high performance liquid chromatography coupled to tandem mass spectrometry. Journal of Chromatography A, 2014, 1345, 128-138.	3.7	9
104	Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4Â-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. Journal of Antimicrobial Chemotherapy, 2014, 69, 3311-3319.	3.0	20
105	Disease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria. Malaria Journal, 2014, 13, 219.	2.3	5
106	Substantially increased sildenafil bioavailability after sublingual administration in children with congenital heart disease: two case reports. Journal of Medical Case Reports, 2014, 8, 171.	0.8	10
107	CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2014, 95, 250-251.	4.7	6
108	Influence of St. JohnÃ¢Â€Â™s wort on the steadystate pharmacokinetics and metabolism of bosentan. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 328-336.	0.6	13

#	Article	IF	Citations
109	Lack of a clinically significant interaction of grapefruit juice with ambrisentan and bosentan in healthy adults. International Journal of Clinical Pharmacology and Therapeutics, 2014, 52, 957-964.	0.6	4
110	Concentration effect relationship of CYP3A inhibition by ritonavir in humans. European Journal of Clinical Pharmacology, 2013, 69, 1795-1800.	1.9	38
111	Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. European Journal of Clinical Pharmacology, 2013, 69, 1785-1793.	1.9	25
112	Reduced exposure variability of the CYP3A substrate simvastatin by dose individualization to CYP3A activity. Journal of Clinical Pharmacology, 2013, 53, 1199-1204.	2.0	9
113	Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics Journal, 2013, 13, 484-489.	2.0	38
114	Steady-state pharmacokinetics and metabolism of voriconazole in patients. Journal of Antimicrobial Chemotherapy, 2013, 68, 2592-2599.	3.0	49
115	Influence of sildenafil and tadalafil on the enzyme- and transporter-inducing effects of bosentan and ambrisentan in LS180 cells. Biochemical Pharmacology, 2013, 85, 265-273.	4.4	50
116	A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions. Clinical Pharmacology and Therapeutics, 2013, 93, 564-571.	4.7	78
117	Liposomal Sphingomyelin Influences the Cellular Lipid Profile of Human Lymphoblastic Leukemia Cells without Effect on P-Glycoprotein Activity. Molecular Pharmaceutics, 2013, 10, 1020-1034.	4.6	6
118	Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. European Journal of Clinical Pharmacology, 2013, 69, 507-513.	1.9	31
119	Trimethoprimâ€“metformin interaction and its genetic modulation by <scp>OCT</scp>2 and <scp>MATE1</scp> transporters. British Journal of Clinical Pharmacology, 2013, 76, 787-796.	2.4	67
120	Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. PLoS ONE, 2013, 8, e67946.	2.5	108
121	Cellular Pharmacokinetic/Pharmacodynamic Relationship of Platinum Cytostatics in Head and Neck Squamous Cell Carcinoma Evaluated by Liquid Chromatography Coupled to Tandem Mass Spectrometry. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 51-58.	2.5	11
122	High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naÃ¯ve HIV patients from Ethiopia: a prospective cohort study. Pharmacogenomics Journal, 2012, 12, 499-506.	2.0	100
123	Drug Interaction of Efavirenz and Midazolam: Efavirenz Activates the CYP3A-Mediated Midazolam 1â€²-Hydroxylation In Vitro. Drug Metabolism and Disposition, 2012, 40, 1178-1182.	3.3	27
124	Quantification of retinoid concentrations in human serum and brain tumor tissues. Analytica Chimica Acta, 2012, 725, 57-66.	5.4	11
125	Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. PLoS ONE, 2012, 7, e40180.	2.5	47
126	Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1â€²-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2012, 402, 2439-2450.	3.7	59

#	Article	IF	Citations
127	A multifunctional bioconjugate module for versatile photoaffinity labeling and click chemistry of RNA. Nucleic Acids Research, 2011, 39, 7348-7360.	14.5	50
128	Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Clinical Pharmacology and Therapeutics, 2011, 90, 406-413.	4.7	70
129	Expanding the chemical scope of RNA:methyltransferases to site-specific alkynylation of RNA for click labeling. Nucleic Acids Research, 2011, 39, 1943-1952.	14.5	114
130	Aberrant Expression of Retinoic Acid Signaling Molecules Influences Patient Survival in Astrocytic Gliomas. American Journal of Pathology, 2011, 178, 1953-1964.	3.8	63
131	Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PLoS ONE, 2011, 6, e27810.	2.5	93
132	Modulators of Very Low Voriconazole Concentrations in Routine Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2011, 33, 86-93.	2.0	60
133	Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy. Clinical Pharmacology and Therapeutics, 2011, 90, 666-673.	4.7	112
134	Daily Honey Consumption Does Not Change CYP3A Activity in Humans. Journal of Clinical Pharmacology, 2011, 51, 1223-1232.	2.0	6
135	Sildenafil Preserves Lung Endothelial Function and Prevents Pulmonary Vascular Remodeling in a Rat Model of Diastolic Heart Failure. Circulation: Heart Failure, 2011, 4, 198-206.	3.9	69
136	Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 2350-2361.	3.0	54
137	The NK₁ receptor antagonist aprepitant does not alter the pharmacokinetics of highâ€dose melphalan chemotherapy in patients with multiple myeloma. British Journal of Clinical Pharmacology, 2010, 70, 903-907.	2.4	22
138	Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Tropical Medicine and International Health, 2010, 15, 713-717.	2.3	40
139	Effect of Simultaneous Induction and Inhibition of CYP3A by St John's Wort and Ritonavir on CYP3A Activity. Clinical Pharmacology and Therapeutics, 2010, 87, 191-196.	4.7	51
140	Long-Term Efavirenz Autoinduction and Its Effect on Plasma Exposure in HIV Patients. Clinical Pharmacology and Therapeutics, 2010, 88, 676-684.	4.7	98
141	No Evidence for Induction of ABC Transporters in Peripheral Blood Mononuclear Cells in Humans after 14 Days of Efavirenz Treatment. Antimicrobial Agents and Chemotherapy, 2010, 54, 4185-4191.	3.2	30
142	Detection of RNA modifications. RNA Biology, 2010, 7, 237-247.	3.1	111
143	Sulphobutylether-Î²-cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. International Journal of Antimicrobial Agents, 2010, 36, 93-94.	2.5	24
144	Pharmacokinetics of Sulfobutylether-Beta-Cyclodextrin and Voriconazole in Patients with End-Stage Renal Failure during Treatment with Two Hemodialysis Systems and Hemodiafiltration. Antimicrobial Agents and Chemotherapy, 2010, 54, 2596-2602.	3.2	75

#	Article	IF	Citations
145	CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole. Journal of Clinical Pharmacology, 2009, 49, 196-204.	2.0	174
146	Efavirenz Treatment and Falseâ€Positive Results in Benzodiazepine Screening Tests. Clinical Infectious Diseases, 2009, 48, 1787-1789.	5.8	18
147	Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent. Hepatology, 2009, 50, 143-154.	7.3	41
148	Turquoise to dark green organs at autopsy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 341-344.	2.8	31
149	High absolute bioavailability of methylene blue given as an aqueous oral formulation. European Journal of Clinical Pharmacology, 2009, 65, 179-189.	1.9	96
150	Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. British Journal of Clinical Pharmacology, 2009, 68, 906-915.	2.4	152
151	Quantification of cationic anti-malaria agent methylene blue in different human biological matrices using cation exchange chromatography coupled to tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 863, 273-282.	2.3	49
152	Marked differences in the prevalence of chloroquine resistance between urban and rural communities in Burkina Faso. Acta Tropica, 2008, 105, 81-86.	2.0	18
153	Cation exchange resins as pharmaceutical carriers for methylene blue: Binding and release. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 582-587.	4.3	20
154	Pharmacokinetics, Tissue Concentrations, and Safety of the Antifungal Agent Voriconazole in Chickens. , 2008, 22, 199-207.		29
155	Induction of Voriconazole Metabolism by Rifampin in a Patient with Acute Myeloid Leukemia: Importance of Interdisciplinary Communication To Prevent Treatment Errors with Complex Medications. Antimicrobial Agents and Chemotherapy, 2007, 51, 3455-3456.	3.2	47
156	Voriconazole Concentration in Human Aqueous Humor and Plasma during Topical or Combined Topical and Systemic Administration for Fungal Keratitis. Antimicrobial Agents and Chemotherapy, 2007, 51, 239-244.	3.2	115
157	Monitoring of lopinavir and ritonavir in peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and highly sensitive LC/MS/MS assay. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 249-258.	2.3	41
158	Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. Rapid Communications in Mass Spectrometry, 2007, 21, 2704-2716.	1.5	55
159	Successful treatment with voriconazole of Aspergillus brain abscess in a boy with medulloblastoma. Pediatric Blood and Cancer, 2007, 49, 203-207.	1.5	13
160	CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir. Clinical Pharmacology and Therapeutics, 2007, 81, 708-712.	4.7	56
161	Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malaria Journal, 2006, 5, 84.	2.3	98
162	Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. International Journal of Antimicrobial Agents, 2006, 28, 262-265.	2.5	46

#	Article	IF	Citations
163	Comparative Bioavailability of the Microemulsion Formulation of Cyclosporine (Neoral) With a Generic Dispersion Formulation (Cicloral) in Young Healthy Male Volunteers. Therapeutic Drug Monitoring, 2006, 28, 312-320.	2.0	9
164	Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clinical Pharmacology, 2006, 6, 6.	2.5	85
165	Potent cytochrome P450 2C19 genotypeâ€“related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clinical Pharmacology and Therapeutics, 2006, 80, 126-135.	4.7	143
166	Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype. Antimicrobial Agents and Chemotherapy, 2006, 50, 3227-3228.	3.2	40
167	Fluvoxamine Affects Sildenafil Kinetics and Dynamics. Journal of Clinical Psychopharmacology, 2005, 25, 589-592.	1.4	12
168	Analysis of methylene blue in human urine by capillary electrophoresis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 826, 244-251.	2.3	27
169	Opposite effects of short-term and long-term St Johnâ€™s wort intake on voriconazole pharmacokinetics. Clinical Pharmacology and Therapeutics, 2005, 78, 25-33.	4.7	130
170	Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso. Tropical Medicine and International Health, 2005, 10, 32-38.	2.3	49
171	Cytochrome P450 enzyme-mediated drug metabolism at exposure to acute hypoxia (corresponding to) Tj ETQq1 1 0.784314 rgBT /O	1.9	25
172	In Vitro Assessment of Methylene Blue on Chloroquine-Sensitive and -Resistant Plasmodium falciparum Strains Reveals Synergistic Action with Artemisinins. Antimicrobial Agents and Chemotherapy, 2005, 49, 4592-4597.	3.2	99
173	Structure of the Toxaphene Compound 2,5-endo,6- exo,8,9,9,10,10-Octachlorobornene-2:â€‰ A Temperature-Dependent Formation of Two Rotamers. Environmental Science & Technology, 2005, 39, 1736-1740.	10.0	2
174	Safety of the methylene blue plus chloroquine combination in the treatment of uncomplicated falciparum malaria in young children of Burkina Faso [ISRCTN27290841]. Malaria Journal, 2005, 4, 45.	2.3	59
175	Oral Contraception Does Not Alter Single Dose Saquinavir Pharmacokinetics in Women. British Journal of Clinical Pharmacology, 2004, 57, 244-252.	2.4	25
176	Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. British Journal of Clinical Pharmacology, 2004, 58, 443-444.	2.4	51
177	Undeclared exposure to St. John's Wort in hospitalized patients. British Journal of Clinical Pharmacology, 2004, 58, 437-441.	2.4	36
178	Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochemical Pharmacology, 2004, 67, 285-292.	4.4	37
179	Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. European Journal of Clinical Pharmacology, 2004, 60, 709-715.	1.9	73
180	Simultaneous determination of hypericin and hyperforin in human plasma with liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 813, 27-33.	2.3	15

#	Article	IF	Citations
181	Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers*1. Clinical Pharmacology and Therapeutics, 2004, 76, 73-84.	4.7	152
182	Reduction of Saquinavir Exposure by Coadministration of Loperamide. Clinical Pharmacokinetics, 2004, 43, 1015-1024.	3.5	8
183	Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clinical Pharmacology and Therapeutics, 2003, 73, 397-405.	4.7	86
184	Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. British Journal of Clinical Pharmacology, 2003, 56, 32-38.	2.4	126
185	Highly sensitive determination of saquinavir in biological samples using liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 784, 233-242.	2.3	19
186	Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL. British Journal of Clinical Pharmacology, 2002, 53, 576-581.	2.4	75
187	Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. Aids, 2002, 16, 674-676.	2.2	16
188	Ritonavir increases loperamide plasma concentrations without evidence for P-glycoprotein involvement. Clinical Pharmacology and Therapeutics, 2001, 70, 405-414.	4.7	45
189	Rapid Target Analysis for Pesticides in Water by Online Coated Capillary Microextraction Combined with Liquid Chromatography and Tandem Mass Spectrometry. Journal of AOAC INTERNATIONAL, 2000, 83, 762-770.	1.5	14
190	Development of capillary electrophoresis methods for the analysis of fluoroquinolones and application to the study of the influence of humic substances on their photodegradation in aqueous phase. Journal of Chromatography A, 1999, 837, 253-265.	3.7	120
191	Polar photodegradation products of quinolones determined by HPLC/MS/MS. Chemosphere, 1999, 38, 1279-1286.	8.2	44
192	The role of biotic and abiotic degradation processes during the formation of typical toxaphene peak patterns in aquatic biota. Chemosphere, 1999, 39, 563-568.	8.2	12
193	Binding of Fluoroquinolone Carboxylic Acid Derivatives to Clay Minerals. Journal of Agricultural and Food Chemistry, 1997, 45, 1459-1463.	5.2	248
194	Primary photoproducts and half-lives. Environmental Science and Pollution Research, 1997, 4, 10-15.	5.3	98
195	Photolytic degradation of fluoroquinolone carboxylic acids in aqueous solution. Environmental Science and Pollution Research, 1997, 4, 61-67.	5.3	66
196	Spectroscopic characterization of environmentally relevant C10-chloroterpenes from a photochemically modified toxaphene standard. Fresenius' Journal of Analytical Chemistry, 1995, 351, 271-285.	1.5	69
197	HRGC-ECD and HRGC-NICI SIM quantification of toxaphene residues in selected marine organism by environmentally relevant chlorobornanes as standard. Chemosphere, 1994, 28, 237-243.	8.2	28
198	Theoretical consideration of the structural variety in the toxaphene mixture taking into account recent experimental results. Chemosphere, 1994, 28, 245-252.	8.2	38

#	Article	IF	Citations
199	Structure elucidation of the three most important toxaphene congeners by X-ray analysis. Chemosphere, 1994, 28, 2067-2074.	8.2	25
200	Preparation and structure of high-chlorinated bornane derivatives for the quantification of toxaphene residues in environmental samples. Fresenius' Journal of Analytical Chemistry, 1993, 346, 779-785.	1.5	71
201	Isolation and characterization of environmental relevant single toxaphene components. Chemosphere, 1993, 27, 1857-1863.	8.2	26